Cargando…

Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies

BACKGROUND: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Chorath, Kevin T., Willis, Matthew J., Morton-Gonzaba, Nicolas, Humann, Walter J., Moreira, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535185/
https://www.ncbi.nlm.nih.gov/pubmed/31128597
http://dx.doi.org/10.1186/s13643-019-1015-7
_version_ 1783421553051959296
author Chorath, Kevin T.
Willis, Matthew J.
Morton-Gonzaba, Nicolas
Humann, Walter J.
Moreira, Alvaro
author_facet Chorath, Kevin T.
Willis, Matthew J.
Morton-Gonzaba, Nicolas
Humann, Walter J.
Moreira, Alvaro
author_sort Chorath, Kevin T.
collection PubMed
description BACKGROUND: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models. METHODS: We will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-naïve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger’s regression tests, respectively. DISCUSSION: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies. SYSTEMATIC REVIEW REGISTRATION: CAMARADES (http://www.dcn.ed.ac.uk/camarades/) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13643-019-1015-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6535185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65351852019-05-30 Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies Chorath, Kevin T. Willis, Matthew J. Morton-Gonzaba, Nicolas Humann, Walter J. Moreira, Alvaro Syst Rev Protocol BACKGROUND: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models. METHODS: We will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-naïve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger’s regression tests, respectively. DISCUSSION: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies. SYSTEMATIC REVIEW REGISTRATION: CAMARADES (http://www.dcn.ed.ac.uk/camarades/) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13643-019-1015-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-25 /pmc/articles/PMC6535185/ /pubmed/31128597 http://dx.doi.org/10.1186/s13643-019-1015-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Protocol
Chorath, Kevin T.
Willis, Matthew J.
Morton-Gonzaba, Nicolas
Humann, Walter J.
Moreira, Alvaro
Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
title Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
title_full Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
title_fullStr Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
title_full_unstemmed Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
title_short Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
title_sort mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535185/
https://www.ncbi.nlm.nih.gov/pubmed/31128597
http://dx.doi.org/10.1186/s13643-019-1015-7
work_keys_str_mv AT chorathkevint mesenchymalstemcellsforsensorineuralhearinglossprotocolforasystematicreviewofpreclinicalstudies
AT willismatthewj mesenchymalstemcellsforsensorineuralhearinglossprotocolforasystematicreviewofpreclinicalstudies
AT mortongonzabanicolas mesenchymalstemcellsforsensorineuralhearinglossprotocolforasystematicreviewofpreclinicalstudies
AT humannwalterj mesenchymalstemcellsforsensorineuralhearinglossprotocolforasystematicreviewofpreclinicalstudies
AT moreiraalvaro mesenchymalstemcellsforsensorineuralhearinglossprotocolforasystematicreviewofpreclinicalstudies